Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bayesian decision procedures for binary and continuous bivariate dose-escalation studies.

Yinghui Zhou1, John Whitehead, Elisa Bonvini

  • 1Medical and Pharmaceutical Statistics Research Unit, The University of Reading, UK. y.zhou@reading.ac.uk

Pharmaceutical Statistics
|November 4, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The circadian clock gene CYCLE as a potential target for disrupting blood-feeding behavior in the mosquito Culex pipiens.

PLoS neglected tropical diseases·2026
Same author

Corrigendum to "Pipiserpin orchestrates mosquito reproduction through dual control of vitellogenin integrity and 20-hydroxyecdysone-directed vitellogenesis" [Insect Biochem. Molec. Biol. 189 (2026) 104514].

Insect biochemistry and molecular biology·2026
Same author

Pipiserpin orchestrates mosquito reproduction through dual control of vitellogenin integrity and 20-hydroxyecdysone-directed vitellogenesis.

Insect biochemistry and molecular biology·2026
Same author

Lnc-Gm26626 in visceral adipose tissues participates in energy metabolism via IDH3α-associated tricarboxylic acid cycle activity.

The Journal of nutritional biochemistry·2025
Same author

Multi-oil fat emulsion improves postoperative nutritional status and reduces complications in patients with hilar cholangiocarcinoma.

Frontiers in nutrition·2025
Same author

A sudden appearance of pink-yellow papules: the grave and pressing significance underlying skin lesions.

Internal and emergency medicine·2025
Same journal

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.

Pharmaceutical statistics·2026
Same journal

Harmonic Fowlkes-Mallows Index for Medical Diagnostics Tests and Optimal Cut-Off Point Selection of Binary Diseases.

Pharmaceutical statistics·2026
Same journal

Early Phase Dose-Finding Designs for CAR-T Cell Therapies.

Pharmaceutical statistics·2026
Same journal

Optimizing Randomization Ratios in Clinical Trials With Survival Endpoints.

Pharmaceutical statistics·2026
Same journal

CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized Trials.

Pharmaceutical statistics·2026
Same journal

Will the Pharmaceutical Industry Need Statisticians in an AI World?

Pharmaceutical statistics·2026
See all related articles

Bayesian decision procedures enhance dose-escalation studies by integrating both safety (undesirable events) and efficacy (therapeutic benefit) measures. These methods offer a flexible framework for optimizing clinical trial designs.

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Pharmacometrics

Background:

  • Dose-escalation studies are critical for determining optimal drug dosages.
  • Existing methods often analyze safety and efficacy outcomes separately or use binary measures exclusively.
  • There is a need for integrated approaches that can handle diverse outcome types.

Purpose of the Study:

  • To develop advanced Bayesian decision procedures for dose-escalation studies.
  • To generalize existing methods by incorporating both binary safety and continuous efficacy data.
  • To provide a robust framework for optimizing dose selection in clinical trials.

Main Methods:

  • Utilized logistic regression for binary undesirable events.
  • Employed linear regression for continuous therapeutic benefit measures.

Related Experiment Videos

  • Incorporated prior distributions and a gain function for decision-making.
  • Included an optional safety constraint for risk management.

    • Main Results:

    • Developed novel Bayesian decision procedures for dose-escalation.
    • Successfully generalized methods to accommodate mixed binary and continuous outcomes.
    • Demonstrated a framework for integrating safety and efficacy data within a unified model.
    • The proposed methods allow for flexible prior specification and incorporate safety constraints.

    Conclusions:

    • The developed Bayesian procedures offer a powerful and flexible approach to dose-escalation studies.
    • These methods enable the simultaneous optimization of safety and efficacy.
    • The framework is applicable to a wider range of clinical trial designs involving mixed outcome data.